OpGen, Inc. (OPGN) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of OpGen, Inc. (NASDAQ:OPGN) from a buy rating to a hold rating in a research note published on Wednesday morning.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

A number of other research firms have also recently commented on OPGN. Dawson James reissued a buy rating on shares of OpGen in a research note on Monday, June 19th. HC Wainwright set a $1.00 target price on shares of OpGen and gave the stock a buy rating in a research note on Wednesday, August 9th.

Shares of OpGen (OPGN) traded down 2.7835% on Wednesday, hitting $0.2829. The stock had a trading volume of 947,689 shares. The firm’s 50-day moving average price is $0.30 and its 200 day moving average price is $0.63. The firm’s market cap is $14.59 million. OpGen has a 12 month low of $0.27 and a 12 month high of $3.10.

COPYRIGHT VIOLATION NOTICE: “OpGen, Inc. (OPGN) Cut to “Hold” at Zacks Investment Research” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2017/09/16/opgen-inc-opgn-cut-to-hold-at-zacks-investment-research.html.

In other OpGen news, CFO Timothy C. Dec acquired 65,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The stock was bought at an average price of $0.40 per share, with a total value of $26,000.00. Following the purchase, the chief financial officer now owns 118,966 shares in the company, valued at $47,586.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Jven Capital, Llc acquired 1,875,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The shares were acquired at an average cost of $0.40 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here. 53.27% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its holdings in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 342,860 shares of the medical research company’s stock after acquiring an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 at the end of the most recent reporting period. 8.13% of the stock is currently owned by institutional investors and hedge funds.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply